磷酸依托泊苷
| 中文名稱 | 磷酸依托泊苷 |
|---|---|
| 中文同義詞 | 依托泊苷磷酸酯(磷酸依托泊甙、磷酸依托泊苷);依托泊苷磷酸酯;磷酸依托泊甙;磷酸依托泊苷;依托泊甙磷酸酯 |
| 英文名稱 | Etoposide phosphate |
| 英文同義詞 | ETOPOSIDE PHOSPHATE;ETOPOSIDE PHOSPHONATE;ETOPOSIDE PHOSPHONATE, ETOPOPHOS;BMY-40481, Etoposide 4'-Dihydrogenphosphate;Etoposide 4'-Phosphate;(5R,5aR,8aR,9S)-5-[3,5-DiMethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one;[5R-[5α,5aβ,8aα,9β(R*)]]-5-[3,5-DiMethoxy-4-(phosphonooxy)phenyl]-9-[(4,6-O-ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one;BMY 40481 |
| CAS號 | 117091-64-2 |
| 分子式 | C29H33O16P |
| 分子量 | 668.54 |
| EINECS號 | 630-364-1 |
| 相關(guān)類別 | 信號轉(zhuǎn)導(dǎo)通路激酶抑制劑;Antineoplastic;Carbohydrates & Derivatives;Drug Analogues;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API |
| Mol文件 | 117091-64-2.mol |
| 結(jié)構(gòu)式 |  |
磷酸依托泊苷 性質(zhì)
| 沸點 | 907.7±75.0 °C(Predicted) |
|---|---|
| 密度 | 1?+-.0.1 g/cm3(Predicted) |
| 儲存條件 | -20°C |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 1.13±0.50(Predicted) |
| 顏色 | 白色至米白色 |
| 水溶解性 | Water: 125 mg/mL (186.97 mM) |
|
Topoisomerase II
|
Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule.Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW +/+ , FBXW -/- and p53 -/- as a dose-dependent manner, exhibits IC 50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively.Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7 -/- cells.
Cell Viability Assay
| Cell Line: | FBXW +/+ , FBXW -/- and p53 -/- cell |
| Concentration: | 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibited HCT116 FBXW +/+ , FBXW -/- and p53 -/- cell growth as a concentration manner. |
Western Blot Analysis
| Cell Line: | HCT116 FBXW7 +/+ or FBXW7 -/- cells |
| Concentration: | 25 μM |
| Incubation Time: | 6 hours |
| Result: | Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7. |
Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8?in female CD-1 mice.
| Animal Model: | Female CD-1 mice |
| Dosage: | 50, 100, or 150 mg/kg |
| Administration: | Intravenous injection; single dose |
| Result: | Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM). |
安全信息
| 海關(guān)編碼 | 2938909090 |
|---|
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-13630 | 磷酸依托泊苷 Etoposide phosphate | 117091-64-2 | 5mg | 800元 |
| 2025/05/22 | HY-13630 | 磷酸依托泊苷 Etoposide phosphate | 117091-64-2 | 10mM * 1mLin Water | 1177元 |